Since joining Amedisys (Nasdaq: AMED) in 2014, CEO Paul Kusserow has spearheaded an ambitious turnaround effort, during which time the company’s stock has climbed from around $20 per share to the more than $130 per share range it sits at today.

Most of Amedisys’ growth over the years has come organically, though the Baton Rouge, Louisiana-based company has been active on the M&A front as well, reflected by its two recent hospice deals.

Listen to this episode of Disrupt to learn:

- What Amedisys is doing to prepare for PDGM

- How the company has grown over the last four years

- Why Amedisys is becoming an even bigger hospice player

- …And much more!